Clinical trial
A First-in-man Phase I/II Single-agent Open-label Dose-escalation Study of Every Three-week Dosing of Oral ONC201 in Patients With Advanced Cancer and Limited Treatment Options
NCT02038699 is registered in ClinicalTrials.gov with Jazz Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A First-in-man Phase I/II Single-agent Open-label Dose-escalation Study of Every Three-week Dosing of Oral ONC201 in Patients With Advanced Cancer and Limited Treatment Options
- Lead sponsor
- Jazz Pharmaceuticals
- Phase
- Phase 1/2
- Overall status
- Withdrawn
- Start date
- January 31, 2014
- Completion date
- December 31, 2016
- Enrollment
- 0 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
advanced colorectal cancer, advanced glioblastoma, advanced non-small cell lung cancer, advanced triple-negative breast cancer